GEVO Gevo, Inc.
Industrial Organic Chemicals · Nasdaq · SEC CIK 1392380 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY80.1%
TTM net income YoY-303.6%
TTM EPS YoY-261.9%
Revenue 3-yr CAGR153.5%
Net income 3-yr CAGR—
Margins
Gross margin51.2%
Operating margin-68.2%
Net margin-83.7%
FCF margin-14.2%
EBITDA margin-56.5%
Returns
ROE-47.5%
ROA-29.7%
ROIC (approx.)-24.5%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets42.9%
Debt / equity0.56x
Current ratio2.04x
Interest coverage-7.05x
Cash quality & payout
Operating cash flow / net income-0.18x
Accruals ratio-35.0%
Payout ratio—
Capex / revenue28.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $160.58M | $16.91M | $17.20M | $1.18M | $533,000 |
| Cost of revenue | $85.24M | $12.00M | $11.99M | $8.70M | $7.69M |
| Gross profit | $75.34M | $4.91M | $5.21M | -$7.52M | -$11.45M |
| R&D expense | $4.55M | $5.58M | $6.64M | $7.43M | $6.78M |
| SG&A expense | $51.20M | $45.80M | $42.63M | $39.94M | $25.49M |
| Operating income | -$20.21M | -$90.82M | -$81.83M | -$102.69M | -$60.27M |
| Interest expense | $17.56M | $3.88M | $2.16M | $1.17M | $251,000 |
| Pretax income | -$32.63M | -$78.64M | — | — | — |
| Net income | -$33.84M | -$78.64M | -$66.22M | -$98.01M | -$59.20M |
| EBITDA | $5.11M | -$72.53M | -$62.83M | -$94.80M | -$55.14M |
| EPS (basic) | -0.14 | -0.34 | -0.28 | -0.44 | -0.30 |
| EPS (diluted) | -0.14 | -0.34 | -0.28 | -0.44 | -0.30 |
| Weighted avg. shares (diluted) | 234.01M | 231.67M | 238.69M | 221.54M | 195.79M |
| Balance sheet | |||||
| Cash & equivalents | $81.16M | $259.03M | $375.60M | $315.38M | $136.03M |
| Short-term investments | — | — | — | $167.41M | $275.34M |
| Receivables | $8.39M | $2.41M | $2.62M | $476,000 | $978,000 |
| Inventory | $19.08M | $4.50M | $3.81M | $6.35M | $2.75M |
| Current assets | $143.40M | $203.71M | $386.38M | $415.42M | $348.54M |
| PP&E, net | $353.58M | $221.64M | $211.56M | $185.17M | $137.74M |
| Goodwill | $43.56M | $3.74M | — | — | — |
| Intangibles | $95.00M | $8.13M | $6.52M | $7.69M | $8.94M |
| Total assets | $718.93M | $583.94M | $650.32M | $700.75M | $645.38M |
| Current liabilities | $78.58M | $24.36M | $91.43M | $25.44M | $29.09M |
| Short-term debt | $0 | $21,000 | $68.10M | $159,000 | $158,000 |
| Long-term debt | $164.75M | $67.11M | $21,000 | $67.38M | $66.80M |
| Total debt | $164.75M | $67.13M | $68.12M | $67.54M | $66.96M |
| Total liabilities | $247.76M | $94.45M | $92.93M | $95.27M | $98.13M |
| Shareholders' equity | $466.34M | $489.49M | $557.39M | $605.48M | $547.25M |
| Net debt | $83.59M | -$191.90M | -$307.48M | -$247.84M | -$69.07M |
| Shares outstanding | 242.46M | 239.18M | 240.50M | 237.17M | 201.99M |
| Cash flow statement | |||||
| Operating cash flow | -$13.40M | -$57.38M | -$53.72M | -$44.31M | -$48.27M |
| Capital expenditure | $30.11M | $51.09M | $54.45M | $84.08M | $56.77M |
| Free cash flow | -$43.51M | -$108.47M | -$108.17M | -$128.39M | -$105.04M |
| Investing cash flow | -$226.57M | -$51.82M | $114.13M | $85.09M | -$411.36M |
| Financing cash flow | $97.88M | -$7.36M | -$189,000 | $138.56M | $517.32M |
| Depreciation & amortization | $25.32M | $18.30M | $19.01M | $7.89M | $5.13M |
| Stock-based compensation | $9.21M | $14.73M | $17.09M | $17.42M | $9.87M |
| Share buybacks | — | $4.71M | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 20 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.